Table 3.
Odds ratios (OR, with 95% confidence interval [CI]) for the association between HIV status and Any Depressive Symptoms, before and after adjustment for each biomarker fitted separately.
| Biomarker | N |
N Any Depressive Symptoms |
OR (95% CI) for Any Depressive Symptoms, adjusted for HIV status and sociodemographic factors |
|
|---|---|---|---|---|
| Before adjusting for biomarker | Adjusted for biomarker | |||
| Neurometabolitesa | ||||
| Myo-inositol | ||||
| Frontal White Matter | 161 | 29 | 2.96 (1.12, 9.13) | 3.23 (1.19, 10.15) |
| Putamen | 63 | 20 | 5.19 (1.32, 27.63) | 5.55 (1.35, 30.35) |
| Choline | ||||
| Frontal White Matter | 184 | 36 | 2.75 (1.17, 7.20) | 2.91 (1.21, 7.74) |
| Putamen | 128 | 29 | 7.46 (2.26, 35.53) | 8.54 (2.50, 41.47) |
|
Soluble biomarkers measured in all participants, where possible | ||||
| Plasma | ||||
| CRP | 204 | 42 | 3.27 (1.46, 8.09) | 3.05 (1.34, 7.61) |
| I-FABP | 202 | 41 | 3.81 (1.65, 9.91) | 3.98 (1.62, 10.86) |
| Kyn:Trp | 203 | 41 | 3.76 (1.63, 9.78) | 3.63 (1.54, 9.59) |
| Neopterin | 203 | 41 | 3.76 (1.63, 9.78) | 3.50 (1.44, 9.45) |
| NFL | 202 | 41 | 3.16 (1.41, 7.80) | 2.94 (1.29, 7.31) |
| sCD14 | 201 | 40 | 3.01 (1.34, 7.49) | 3.22 (1.39, 8.20) |
| sCD16 | 202 | 42 | 3.36 (1.50, 8.30) | 3.27 (1.44, 8.18) |
| sCD163 | 204 | 42 | 3.27 (1.46, 8.09) | 3.62 (1.59, 9.11) |
| CSF | ||||
| Kyn:Trp | 202 | 41 | 3.07 (1.37, 7.57) | 3.04 (1.34, 7.62) |
| Neopterin | 202 | 41 | 3.07 (1.37, 7.57) | 2.84 (1.25, 7.11) |
| NFL | 203 | 41 | 3.13 (1.40, 7.80) | 3.15 (1.40, 7.82) |
| sCD14 | 202 | 41 | 3.08 (1.38, 7.62) | 3.14 (1.39, 7.78) |
| sCD163 | 203 | 41 | 3.13 (1.40, 7.72) | 3.28 (1.46, 8.13) |
|
Soluble biomarkers measured in a subset of 78 participants | ||||
| Plasma | ||||
| IL-6 | 78 | 13 | 1.67 (0.46, 6.58) | 1.51 (0.40, 6.01) |
| IP-10/CXCL10 | 78 | 13 | 1.67 (0.46, 6.58) | 1.68 (0.45, 6.69) |
| MCP-1/CCL2 | 78 | 13 | 1.67 (0.46, 6.58) | 1.67 (0.46, 6.59) |
| MIG/CXCL9 | 78 | 13 | 1.67 (0.46, 6.58) | 1.42 (0.38, 5.63) |
| MIP1-α/CCL3 | 78 | 13 | 1.67 (0.46, 6.58) | 1.74 (0.47, 7.00) |
| RANTES/CCL5 | 78 | 13 | 1.67 (0.46, 6.58) | 1.55 (0.41, 6.20) |
| TNF-α | 78 | 13 | 1.67 (0.46, 6.58) | 1.48 (0.39, 5.98) |
| CSF | ||||
| IL-6 | 78 | 13 | 1.67 (0.46, 6.58) | 1.37 (0.35, 5.59) |
| IP-10/CXCL10 | 78 | 13 | 1.67 (0.46, 6.58) | 1.75 (0.46, 7.16) |
| MCP-1/CCL2 | 78 | 13 | 1.67 (0.46, 6.58) | 1.67 (0.45, 6.58) |
| MIG/CXCL9 | 78 | 13 | 1.67 (0.46, 6.58) | 1.66 (0.45, 6.58) |
| MIP1-α/CCL3 | 78 | 13 | 1.67 (0.46, 6.58) | 1.32 (0.35, 5.26) |
| RANTES/CCL5 | 78 | 13 | 1.67 (0.46, 6.58) | 1.64 (0.45, 6.47) |
| TNF-α | 78 | 13 | 1.67 (0.46, 6.58) | 1.83 (0.49, 7.31) |
All models were adjusted for age, sex, ethnicity and years of education.
aModels which included neurometabolite measures were further corrected for scanner.